UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 9, 2006
Lifeline Therapeutics, Inc.
| Colorado | 000-30489 | 84-1097796 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
6400 South Fiddler’s Green Circle, Suite 1970, Englewood, CO 80111
Registrant’s telephone number, including area code: (720) 488-1711
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure
On February 9, 2006, Lifeline Therapeutics, Inc. issued a press release entitled “Dr. Sean
O’Connell Joins Lifeline Therapeutics, Inc. Scientific Advisory Board.” The press release is
attached as Exhibit 99.1 hereto.
Item 9.01 Exhibits
99.1 Press Release, dated February 9, 2006, entitled “Dr. Sean O’Connell Joins Lifeline
Therapeutics, Inc. Scientific Advisory Board.”
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
Date: February 9, 2006
| LIFELINE THERAPEUTICS, INC. |
||||
| By: | /s/ Gerald J. Houston | |||
| Gerald J. Houston | ||||
| Chief Financial Officer | ||||
EXHIBIT INDEX
| Exhibit No. | Description | |
99.1
|
Press Release, dated February 9, 2006, entitled “Dr. Sean O’Connell Joins Lifeline Therapeutics, Inc. Scientific Advisory Board.” |
EXHIBIT 99.1
FOR IMMEDIATE RELEASE
|
NEWS | |
February 9, 2006
|
OTCBB: LFLT |
DR. SEAN O’CONNELL JOINS LIFELINE THERAPEUTICS, INC.
SCIENTIFIC ADVISORY BOARD
SCIENTIFIC ADVISORY BOARD
DENVER, Colorado — Lifeline Therapeutics, Inc. (“Lifeline” or the “Company”) (OTCBB: LFLT), maker
of Protandim®, announced today that Sean M. O’Connell, Ph.D. has joined its Scientific
Advisory Board.
Dr. O’Connell is the Chief Medical Officer for Cascade Medical Enterprises, LLC where he is
responsible for oversight of pre-clinical, clinical and post-marketing development programs for the
FIBRINET orthopaedic/sports medicine and oral surgery/dental implant businesses. He is also
responsible for the creation of a wound care business unit, advocacy development, publication
strategy and plan management, new technology evaluation and business development, and regulatory
affairs.
Dr. O’Connell also serves as Assistant Professor, Department of Surgery, Division of Vascular
Surgery at Englewood Hospital and Medical Center, a Mount Sinai School of Medicine Affiliated
Hospital in Englewood, New Jersey, where he provides oversight of pre-clinical and clinical
research programs.
Prior to this service, Dr. O’Connell was Medical Director for Sandoz Pharmaceuticals and then
became Medical Marketing Director for Novartis Pharmaceuticals Corporation in the Transplant/Tissue
Engineering Business Unit located in East Hanover, New Jersey.
Dr. O’Connell served as Assistant Professor and Head of the Surgical Oncology Research Lab, as well
as Acting Head of the Flow Cytometry/Cell Sorting Lab, at University of Medicine and Dentistry of
New Jersey, Robert Wood Johnson Medical School, Department of
Surgery, New Brunswick, New Jersey.
“Dr. O’Connell’s experience in science, clinical research, and medical applications, along with his
business history will make him an outstanding addition to Lifeline’s Scientific Advisory Board”,
stated Stephen K. Onody, Lifeline Therapeutics Chief Executive Officer. “His background in
molecular and cellular biology and immunology will also complement the Company’s scientific and
research objectives.”
Joe McCord, Ph.D., Director of Science for Lifeline, stated “Dr. O’Connell’s broad range of
academic and business experience further strengthens the Company’s Scientific Advisory Board.”
Dr. O’Connell commented, “I believe Lifeline’s antioxidant technology is extremely exciting. I am
looking forward to working with the Company’s distinguished team and exploring ways to complement,
and possibly expand, the Company’s opportunities.”
Dr. O’Connell received his Ph.D. in immunology and molecular biology from Rutgers University and
the University of Medicine and Dentistry of New Jersey at New Brunswick. He received his
undergraduate degree in biochemistry from the University of Illinois. He completed post-doctoral
fellowship at the Center for Advanced Biotechnology and Medicine.
Dr. O’Connell’s honors include the Charles and Johanna Busch Fellowship and Sigma Xi — Scientific
Research Society, John Deere Chapter. His professional memberships include the International
Society of Analytical Cytology, American Association for the Advancement of Science, Association
for Advanced Wound Care/Medical Research Forum on Wound Repair and the Wound Healing
Society/European Tissue Repair Society.
About Lifeline Therapeutics
Lifeline Therapeutics, Inc. markets Protandim®, a patent-pending dietary supplement that increases
the body’s natural antioxidant protection. Lifeline Therapeutics is committed to helping people
achieve health and wellness ... for life. For more information, please visit the Protandim®
product website at http://www.protandim.com.
Oxidative stress (cell damage caused by free radicals) occurs as a person ages or is subjected to
stresses such as certain illnesses. TBARS are harmful, reactive substances that indicate the level
of oxidative stress in the body. New data from a scientific study in men and women show that after
30 days of taking Protandim®, the level of circulating TBARS decreased an average of 40 percent,
and the age-related increase in TBARS was eliminated. Protandim® strengthens a person’s defenses
against oxidative stress by increasing the body’s natural activity of antioxidant enzymes.
Except for historical information contained herein, this document contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995 and
applicable common law. These statements involve known and unknown risks and uncertainties that may
cause the Company’s actual results or outcomes to be materially different from those anticipated
and discussed herein. Further, the Company operates in industries where securities values may be
volatile and may be influenced by regulatory and other factors beyond the Company’s control. Other
important factors that the Company believes might cause such differences include the Company’s
limited cash flow and the rapid development of technology, lack of liquidity for the Company’s
common stock, working capital shortages, the length of time for scientific advances to reach the
market (if they ever reach the market), among other risks. In assessing forward-looking statements
contained herein, readers are urged to carefully read all cautionary statements contained in the
Company’s filings with the Securities and Exchange Commission.
CONTACT:
Lifeline Therapeutics Inc |
||||
Stephen K. Onody, CEO
|
Telephone: | 720-488-1711 | ||
Gerald J. Houston, CFO
|
Fax: | 303-565-8700 |